ProLectin-I

ProLectin-I is an intravenous galectin-3 antagonist developed by Bioxytran, Inc., primarily for the treatment of severe viral infections, including COVID-19. It is a complex carbohydrate molecule designed to bind to the carbohydrate-recognition domain (CRD) of Galectin-3, a protein that plays a pivotal role in viral attachment, host cell entry, and the modulation of the inflammatory response. By inhibiting Galectin-3, ProLectin-I aims to block viral replication and mitigate the hyper-inflammation (cytokine storm) often associated with advanced respiratory distress. The drug is part of a broader platform of galectin antagonists that includes oral formulations, with ProLectin-I specifically optimized for rapid systemic delivery in hospitalized patients.

Brand names

ProLectin-I

Other names

Galectin-3 antagonistGalectin3 antagonistGalectin 3 antagonistComplex carbohydrate galectin inhibitor